An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Teladoc Health has partnered with Eli Lilly's LillyDirect and pharmacy provider GiftHealth to expand access to Zepbound, a GLP-1 drug prescribed for weight loss. The partnership allows Teladoc ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...